Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,778.00+1.42%ETH$2,288.53+1.68%GOLD$3,942.10+0.04%OIL$96.73+0.67%
Smart Investors Daily
SID Premium
CR

NASDAQ · CRBP

Corbus Pharmaceuticals Holdings, Inc.

Healthcare · Biotechnology

$3.92

Down-$0.05 (-1.15%)

Updated Nov 3, 2026, 11:16 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
121.59M
P/E ratio
-2.05
Dividend yield
0.00%
52-week range
$3.87 – $12.88
Volume
675.36K
Avg. volume
372.45K

Price performance · CRBP

CRBP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

CRBP closed at $3.92 after 21 trading sessions, down 33.08% for the selected period.

Last close
$3.92
Period change
-33.08%
Period low
$3.92
Period high
$5.85
Daily close
View OHLC price history
CRBP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$4.21$4.23$3.895$3.915675.36K
Oct 30, 2026$4.20$4.31$3.9501$4.222.32M
Oct 29, 2026$4.25$4.34$4.10$4.221.48M
Oct 28, 2026$4.13$4.27$4.085$4.25750.84K
Oct 27, 2026$3.99$4.205$3.97$4.15716.71K
Oct 26, 2026$4.05$4.0756$3.87$3.99847.37K
Oct 23, 2026$4.08$4.08$3.93$4.05372.92K
Oct 22, 2026$4.37$4.52$4.0323$4.13983.76K
Oct 21, 2026$4.45$4.565$4.28$4.285625.94K
Oct 20, 2026$4.48$4.68$4.405$4.42477.64K
Oct 19, 2026$4.54$4.67$4.38$4.46735.79K
Oct 16, 2026$4.35$4.72$4.2201$4.521.07M
Oct 15, 2026$4.40$4.62$4.23$4.331.09M
Oct 14, 2026$4.72$4.8199$4.37$4.411.34M
Oct 13, 2026$5.24$5.26$4.76$4.78654.58K
Oct 12, 2026$5.35$5.4025$5.11$5.271.01M
Oct 9, 2026$5.25$5.6099$5.171$5.38872.8K
Oct 8, 2026$5.80$5.80$5.1301$5.271.35M
Oct 7, 2026$5.72$5.795$5.47$5.491.24M
Oct 6, 2026$5.87$5.995$5.65$5.78707.59K
Oct 5, 2026$6.17$6.17$5.83$5.85793.49K

Latest CRBP news

The latest Smart Investors Daily articles mentioning CRBP.

Stock researchCompany · Overview

CRBP research

Overview

Company profile and research snapshot.

Company profile

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.33
Implied upside
—
Analysts
—
CRBP recent ratings
DateFirmRatingTarget
Sep 14, 2026HC Wainwright & Co.Buy—
Aug 7, 2026HC Wainwright & Co.Buy—
Aug 7, 2026OppenheimerOutperform—
Jun 23, 2026MizuhoOutperform—
Jun 17, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026

NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at Obesity Week® 2026, taking place from November 14–17, 2026 in National Harbor, MD. Title: Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 StudyPresenter: Harold Bays, M.D, Lou

Yahoo · Sep 29, 2026

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By